Molecular mechanisms of MHC linked susceptibility in leprosy: Towards the development of synthetic vaccines

Tuberculosis

Volumn 84, Issue 1-2, 2004, Pages 82-92

  Gorodezky, Clara ^a   Alaez, Carmen ^a   Munguía, Andrea ^a   Cruz, Rocío ^a   Vazquez, Alejandra ^a   Camacho, Alejandra ^a   Flores, Oscar ^b   Rodriguez, Mirna ^b   Rodriguez, Obdulia ^b  

^a Instituto Nacional de Diagnostico y Referencia Epidemiologicos   (Mexico)

^b CENTRO DERMATOLÓGICO DR LADISLAO DE LA PASCUA   (Mexico)

Author keywords

HLA; HLA susceptibility; Immunogenetics; Lepromatous leprosy; Mexicans; MHC; Molecular mechanisms of HLA susceptibility

Indexed keywords

DNA VACCINE; HLA ANTIGEN; LEPROMIN; LEPROSY VACCINE;

BACTERIAL CELL; CELL ACTIVATION; COMPARATIVE STUDY; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DRUG ACTIVITY; EPIDEMIOLOGICAL DATA; FAMILIAL DISEASE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HEALTH STATUS; HISTORY OF MEDICINE; HOMOZYGOSITY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LEPROMATOUS LEPROSY; LYMPHOCYTOTOXICITY; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEXICO; MOLECULAR DYNAMICS; MYCOBACTERIUM LEPRAE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SIBLING; STANDARDIZATION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; VACCINATION;

EID: 0347722523     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2003.08.009     Document Type: Conference Paper

References (77)

1. Hansen AG, Spedalkedenz A, Noesk MF. Leagavid 1879;4: 76-9.
2. Bloom BR. Learning from leprosy: a perspective on immunity and the third world. J Immunol 1986;137:i-x.
3. Ridley DS, Jopling WH. Classification of leprosy according to immunity; a five group system. Int J Lepr 1966;34:255-73.
4. Opromolla DVA. Classificacao. In: Opromolla DVA; Bauru. editor. Nocoes de Hansenologia, Brazil: ILSL; 2000. p. 47-51.
5. Shepard CC. Vaccination of mice against M. leprae infection. Int J Lepr 1976;44:222-6.
6. Curtiss III RS, Blower K, Cooper D, Russell S, Silverstein, Young L. Leprosy research in the post-genome era. Lepr Rev 2001;72:8-22.
7. WHO elimination of leprosy as a public health problem. Wkly Epidemiol Rec 1998;73:308-12.
8. WHO Study Group. Chemotherapy of leprosy. WHO Tech Rep Serv 1994;847-50.
9. Walsh GP, Storrs EE, Burchfield HP, Cotrell EH, Vidrine MF, Binford CH. Leprosy-like disease occurring naturally in armadillos. J Reticuloendoth Soc 1975;18:347-52.
10. Mustafa HM, Kazda J, Irgens LM, Luesse HG. Acid-fast bacilli from former leprosy regions in coastal Norway showing PCR positivity for Mycobacterium leprae. Int J Lepr 1995; 63:97-9.
11. Rees RJW, McDougall AC. Airborne infection with Mycobacterium leprae in mice. J Med Microbiol 1977;10:63-8.
12. Cho SN, Kim SH, Cellon RV, Fajardo TT, Walsh GP, Kim JD. Prevalence of IgM antibodies to phenolic glycolipid I among household contacts and controls in Korea and the Philippines. Lepr Rev 1992;63:12-20.
13. Newell KW. An epidemiologist's view of leprosy. Bull World Health Org 1996;34:827-36.
14. Spickett SG. Genetics and the epidemiology of leprosy.: II: the form of leprosy. Lepr Rev 1962;33:173-89.
15. Gelber RH. Chemotherapy of lepromatous leprosy: recent developments and prospects for the future. Eur J Clin Microbial Infect Dis 1994;13:942-52.
16. Mitsuda K. On the value of a skin reaction to a suspension of leprous nodules. Int J Lepr 1953;21:347-50.
17. Godal T. Immunological aspects of leprosy - present status. Prog Allergy 1978;25:211-6.
18. Narayanan RB, Buthani LK, Sharma AK, Nath I. T-cell subsets in leprosy lesions: in situ characterization using monoclonal antibodies. Clin Exp Immunol 1983;51:421-9.
19. Choudhuri K. Immunology of leprosy. Unravelling an enigma. Editorial: Int J Lepr 1995;63:430-2.
20. Kaplan G, Cohn ZA. Leprosy and cell mediated immunity. Curr Opin Immunol 1991;38:91-6.
21. Kaplan G, Nustrat A, Sarno EN, Job CK, McElrath J, Porto JA, Nathan CF, Cohn ZA. Cellular response to the intradermal injections of recombinant human gamma interferon in lepromatous leprosy patients. Am J Pathol 1987;128:345-53.
22. Kaplan G, Kiessling R, Teklemariam S, Hancock G, Sheftel G, Job CK, Converse P, Ottenhoff TH, Becx-Blumick M, Dietz M, et al. Reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med 1989;169:893-907.
23. Kaplan G. Recent advance in cytokine therapy in leprosy. J Infect Dis 1993;167(Suppl. 1, S18-S22).
24. Rodriguez A. Selective transport of internalized antigens to the cystol for MHC class II presentation in dentritic cells. Nat Cell Biol 1999;6:362-8.
25. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, Bloom BR. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991;254:279-82.
26. Nathan CF, Kaplan G, Levis WR, Nustrat A, Witmer MD, Sherwin SA, Job CK, Horowitz CR, Steinman RM, Cohn ZA. Local and systemic effects of intradermal recombinant interferon gamma in patients with lepromatous leprosy. N Engl J Med 1986;315:6-15.
27. Modlin RLL, Pirmez C, Hofman FM, Torigian V, Uyemura K, Rea TH, Bloom BR, Brenner MB. Lymphocytes bearing antigen specific gamma/delta T cell receptors in human infectious disease lesions. Nature 1989;339:544-8.
28. Chakravatti MR, Rao S. Genetic factors in leprosy: evidence from polymorphisms in twins. Int J Lepr 1984;52:743-7.
29. Shields ED, Russel DA, Pericak-Vence MA. Genetic epidemiology of the susceptibility to leprosy. J Clin Invest 1987;79:1139-43.
30. Abel L, Demeraio F. Detection of major genes for susceptibility to leprosy and subtypes in a Caribbean Island. Desirade Island. Am J Hum Genet 1988;42:256-66.
31. Feiosa MF, Bonecki I, Krieger H, Buguelvan B, Rao DC. The genetic epidemiology of leprosy in a Brazilian population. Am J Hum Genet 1995;56:1179-85.
32. Siddiqui MR, Meisner S, Tosh K, Balakrishnan K, Ghe IS, Fisher SE, Golding M, Narayan NPS, Sitarman T, Sengupta U, Pitchappan R, Hill AVS. A major susceptibility locus for leprosy in India, maps to chromosomes 10p 13. Nat Genet 2001;27:439-41.
33. Stach JL, Delgado G, Tschbozo V, Strobel M, Lagrange PH. Natural resistance to mycobacteria: antimicrobial activity and reactive oxygen intermediate releasing functions of murine macrophages. Ann Immunol (Paris) 1984;135:25-37.
34. Naafs B, Silva E. Factors influencing the development of leprosy: an overview. Int J Lepr 2001;69:26-30.
35. Gorodezky C. Immunogenetics of leprosy. A model to understand host immune mechanisms in mycobacterial diseases. Asia Pacific. J Mol Biol Biotechnol 1994;2:301-15.
36. Serjeantson SW, Wilson SR, Keats BJB. The genetics of leprosy. Ann Hum Biol 1979;6:375-93.
37. Rawlison WD, Basten A, Britton WJ, Serjeantson SW. Leprosy and immunity: genetics and immune function in multiple case families. Immunol Cell Biol 1988;66:9-21.
38. Knight JC, Kwiatkowski D. Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Proc Assoc Am Phys 1999;III:290-8.
39. Alcais A, Sanchez EO, Thuc NV, Lap VD, Oberti J, Lagrange PH, Schurr E, Abel N. Granulomatous reaction to intradermal injection to lepromin is linked to the human NRAMP1 gene in Vietnamese siblings. J Infect Dis 2000; 182:302-8.
40. MHC Sequencing Consortium. Complete sequence, gene map of a human major histocompatibility complex (MHC). Nature 1999;401:921-3.
41. Hill AVS. The immunogenetics of human infectious diseases. Ann Rev Immunol 1998;16:593-617.
42. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000;343:702-9.
43. Glynne PA, Price NM. HLA and infectious diseases. In: Lechler R, Warrens A, editors. HLA in health and disease. Great Britain, London, UK: Academic Press; 2000. p. 299-326 (Chapter 20).
44. Gorodezky C. Papel de la Inmunogenética en la distribución y frecuencia de las enfermedades tropicales. In: Valdespino JL, Velasco O, Escobar A, Del Río A, Ibáñez S, Magos C, editors. Enfermedades Tropicales en Mexico. Mexico City, DF, Mexico: Secretaría de Sañud; 1994. p. 67-82.
45. Escobar-Gutierrez A, Gorodezky C, Salazar-Mallén M. Distribution of the HL-A system lymphocyte antigens in Mexicans. II. Studies in atopics and lepers. Vox Sang 1973;25:151-5.
46. Gorodezky C, Excobar-Gutiérrez A, Latapí F, Castro E. Antígenos HLA en pacientes con lepr. In: Larralde C, editor. Memorias del 1er Congreso Nacional de Inmunología. Morelos México: Oaxtepec; 1976 (Abstract).
47. Wang LM, Kimura A, Satoh M, Mineshita S. HLA linked with leprosy in Southern China. HLA-linked resistance alleles in leprosy. Int J Lepr 1999;67:403-8.
48. van Eden W, van Vries RRP, de Mehra NK. HLA segregation of tuberculoid leprosy: confirmation of the DR2 marker. J Infect Dis 1980;141:693-701.
49. Vries RRP, de Mehra NK, Vaydia MC, et al. HLA-linked control of susceptibility to tuberculoid leprosy and association with HLA-DR types. Tissue Antigens 1980;16:294-304.
50. Schauf V, Ryan S, Scollard D, et al. Leprosy associated with HLA-DR2 and DQW1 in the population of northern Thailand. Tissue Antigens 1985;26:243-7.
51. van Eden W, de Vries RRP, Damaro J, Schreuder I, Leiker DL, VanRood JJ. HLA associated genetic control of the type of leprosy in a population of Surinam. Hum Immunol 1982;4:343-50.
52. Gorodezky C, Flores J, Arévalo N, Castro LE, Silva A, Rodríguez O. Tuberculoid leprosy in Mexicans is associated with HILA-DR3-. Lepr Rev 1987;58:401-6.
53. Joko S, Numaga J, Masuda K, Hirata R. The relationship between types of leprosy (Hansen's disease) based on WHO-MDT classification and HLA class II alleles. Jpn J Lepr 1996;65:121-7.
54. Rani R, Fernandez-Viña MA, Zaheer SA. A study of HLA class II alleles by PCR oligotyping in leprosy patients from North India. Tissue Antigens 1993;42:133-7.
55. Van Eden W, Gonzalez NM, deVries RRP, Convit J, VanRood JJ. HLA-linked control of predisposition to lepromatous leprosy. J Infect Dis 1985;151:9-14.
56. Serjeantson SW. HLA and susceptibility to leprosy. Immunol Rev 1983;70:89-112.
57. Kikuchi I, Zawa T, Hirayama K, Sasasuki T. An HLA-linked gene controls susceptibility to lepromatous leprosy through T-cell regulation. Lepr Rev 1986;57(Suppl. 2):139-42.
58. Gorodezky C. Genes de susceptibilidad y supresión ligados al MHC en la lepra. Doctoral Ph.D. thesis, Mexico City: National School of Biological Sciences, National Polytechnical Institute; 1989.
59. De Vries RRP, Serjeantson SW, Layrisse Z, Gorodezky C, Alvarenga V, Flores J, Castro LE. Leprosy. Joint Report. In: Albert E, Mair W, editors. Histocompatibility testing 1984. Proceedings of the 9th international histocompatibility workshop and conference. Berlin, Germany: Springer; 1984. p. 362-7.
60. Romagnani S. Induction of Th1 and Th2 responses: a key for the natural immune response? Immunol Today 1992;13: 379-81.
61. Salgame S, Convit J, Bloom B. Immunological suppression by CD8+ T-cells is receptor dependent and HLA-DQ restricted. Proc Natl Acad Sci USA 1991;88:2598-602.
62. Bignon JD, Fernandez-Viña MA, Cheneau ML, Fauchet R, Shreuder GM, Marsh SGE, Charron D. HLA DNA class II typing by PCR-SSOP: 12th International Workshop Experience. In: Charron D, editor. Genetic diversity of HLA. Functional and medical implication, Vol. 1. Paris, France: EDK; 1997.
63. Guardiola J, Maffei A, Lauster R, Mitchison NA, Acolla RS, Sartoris S. Functional significance of polymorphism among MHC class II gene promoters. Tissue Antigens 1996;48: 615-25.
64. Lee JL, Kim YH, Kim JD, Kim SJ, Park JH. Molecular analysis of HLA.DR gene expression induced by IFN-gamma in malignant melanoma cell lines. Immunogenetics 1999;49: 289287-94.
65. Roy S, McGuire W, Mascie-Taylor CIGN. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis 1997;176:530-2.
66. Mohagheghpour N, Munn MW, Gelber RH, Engelman EG. Identification of an immunostimulating protein from Mycobacterium leprae. Infect Immunol 1990;58:703-10.
67. Winter N, Triccas JA, Rivoire B. Characterisation of the gene encoding the immunodominant 35kDA protein of Mycobacterium leprae. Mol Microbiol 1995;16:865-76.
68. Triccas JA, Roche PW, Winter N, Feng CG, Butlin CR, Britton WJ. 35 kDA protein is a major target of the human immune response to Mycobacterium leprae. Infect Immunol 1996; 64:5171-7.
69. Martin E, Roche PW, Triccas JA, Britton WJ. DNA encoding a single mycobacterial antigen protects against leprosy infection. Vaccine 2001;19:1391-6.
70. Ottenhoff THM, Klatzer PR, Ivanyi J, Elferink BG, de Will MY, de Vries RRP. Mycobacteium leprae specific protein antigens defined by cloned human helper T-cells. Nature 1986;319:63-6.
71. Emmerich F, Thole J, van Embden J, Kaufmann SHE. A recombinant 64 kiloDalton protein of Mycobacterium bovis Bacillus Calmette-Guerin specifically stimulates human T4 clones reactive to mycobacterial antigens. J Exp Med 1986;163:1024-9.
72. Mehra V, Bloom BR, Bajardi AC, Grisso CL, Sieling PA, Alland D, Convit J, Fan X, Hunter SW, Brennan PJ, Rea TH, Modlin RL. A major T-cell antigen of Mycobacterium leprae is a 10kD heat-shock conjugate protein. J Exp Med 1992; 175:275-84.
73. Oftung F, Knut EA, Lundin RM, Mustafa AS. Human T cell recognition of the Mycobacterium leprae LSR antigen: epitopes and HLA restriction. FEMS Immunol Med Microbiol 1999;24:151-9.
74. Ottenhoff THM, Haanen JBB, Geluk H, Mutis T, Kale B, Thole JER, van Schooten WCA. Regulation of microbacterial heat shock protein-reactive T cells by HLA class II molecules: lessons from leprosy. Immunol Rev 1991;121:171-91.
75. Mitra D-K, Rajalingam R, Taneja V, et al. HLA-DR polymorphism modulates the cytokine profile of Mycobacterium leprae HSP-reactive CD4 T cells. Cytokine Immunol Immunopathol 1997;82:60-7.
76. Urban JL, Horvath SJ, Hood L. Autoimmune T cells immune recognition of normal and variant peptide epitopes and peptide based therapy. Cell 1989;59:257-69.
77. Urban JL, Horvath SJ, Hood L. Mycobacterium leprae. Infect Immunol 1989;64:5171-7.